Cargando…
Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver
BACKGROUND: Many studies have investigated the progression of nonalcoholic fatty liver disease (NAFLD) and its predisposing risk factors, but the conclusions from these studies have been conflicting. More challenging is the fact that no effective treatment is currently available for NAFLD. AIM: To d...
Autores principales: | Shafiq, Muhammad, Walmann, Timothy, Nutalapati, Venkat, Gibson, Cheryl, Zafar, Yousaf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772734/ https://www.ncbi.nlm.nih.gov/pubmed/33442452 http://dx.doi.org/10.4254/wjh.v12.i12.1258 |
Ejemplares similares
-
Identification of Novel Proteins Interacting with Proprotein Convertase Subtilisin/Kexin 9
por: Melendez, Quantil M., et al.
Publicado: (2020) -
Proprotein Convertase Subtilisin/Kexin Type 9 and Inflammation: An Updated Review
por: Wu, Na-Qiong, et al.
Publicado: (2022) -
The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease
por: Kim, Eun Ji, et al.
Publicado: (2020) -
Proprotein Convertase Subtilisin/Kexin 6 in Cardiovascular Biology and Disease
por: Wu, Qingyu, et al.
Publicado: (2022) -
Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9
por: Chen, I-Chih, et al.
Publicado: (2017)